ACTRN12619001423101终止1 期
Phase 1, dose escalating study to determine maximum safe exercise training intensity early after stroke
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1) ischaemic stroke diagnosis based on MRI/CT or clinical diagnosis, 2) are within 3 weeks post stroke, 3) have no pre-morbid or current restrictions to exercise, 4) are able to transfer from a sitting position to a standing position either independently or with physical assistance, 5) are able to provide informed consent to participate in the study
排除标准
- •1) hospitalization for myocardial infarction, heart surgery, or congestive heart failure during the preceding 3 months; 2) significant cardiac pathology (arrhythmia, hypertrophic cardiomyopathy, severe aortic stenosis, or pulmonary embolus); 3) significant pulmonary pathology (i.e. severe chronic obstructive pulmonary disease) and 4) musculoskeletal or neurological problems from conditions other than stroke that would limit the ability to exercise (e.g. Parkinson’s Disease, severe osteoarthritis).
研究者
相似试验
招募中
1 期
A phase 1 dose escalating study of ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours.ACTRN12618001070224Therapim Pty Ltd36
进行中（未招募）
1 期
A Clinical Study to investigate the Safety and Tolerability of VAL201 (new trial drug) in Patients with Locally Advanced or Metastatic (cancer cells which spreads from one part of the body to another) Prostate Cancer and Other Advanced Solid Tumours.EUCTR2013-004009-25-GBValiRx plc81
招募中
不适用
A Phase I clinical study to evaluate the safety and efficacy of allogenic adipose-derived stem cells in the patients with Crohn's fiatula.Symptoms, signs and abnormal clinical and laboratory findings, NECKCT0000188Anterogen6
已完成
1 期
Phase I accelerated dose-escalation study of CYT997 given as an oral capsule every two weeks in patients with advanced solid tumoursCancer - solid malignancies that are metastatic or unresectableCancer - Other cancer typesACTRN12606000520538Cytopia Research Pty Ltd15
进行中（未招募）
不适用
Evaluation of a new vaccine treatment for patients with metastatic skin cancer.First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanomaMedDRA version: 18.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2009-016636-13-DEGlaxoSmithKline Biologicals106